|
1
|
Ottaviani G and Jaffe N: The epidemiology
of osteosarcoma. Cancer treatment and research. 152:3–13. 2009.
View Article : Google Scholar
|
|
2
|
Dorfman HD and Czerniak B: Bone cancers.
Cancer. 75:203–210. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Meyers PA, Heller G, Healey J, et al:
Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial
Sloan-Kettering experience. J Clin Oncol. 10:5–15. 1992.PubMed/NCBI
|
|
4
|
Ambros V: MicroRNA pathways in flies and
worms: growth, death, fat, stress, and timing. Cell. 113:673–676.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bartel DP: MicroRNAs: target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Brennecke J, Hipfner DR, Stark A, Russell
RB and Cohen SM: bantam encodes a developmentally regulated
microRNA that controls cell proliferation and regulates the
proapoptotic gene hid in Drosophila. Cell. 113:25–36. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Reinhart BJ, Slack FJ, Basson M, et al:
The 21-nucleotide let-7 RNA regulates developmental timing in
Caenorhabditis elegans. Nature. 403:901–906. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Esquela-Kerscher A and Slack FJ:
Oncomirs-microRNAs with a role in cancer. Nature Revs Cancer.
6:259–269. 2006. View
Article : Google Scholar
|
|
9
|
Wang D, Qiu C, Zhang H, Wang J, Cui Q and
Yin Y: Human microRNA oncogenes and tumor suppressors show
significantly different biological patterns: from functions to
targets. PLoS One. 5:e130672010. View Article : Google Scholar
|
|
10
|
Zhang B, Pan X, Cobb GP and Anderson TA:
microRNAs as oncogenes and tumor suppressors. Dev Biol. 302:1–12.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chen CZ: MicroRNAs as oncogenes and tumor
suppressors. N Engl J Med. 353:1768–1771. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ventura A and Jacks T: MicroRNAs and
cancer: short RNAs go a long way. Cell. 136:586–591. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Spizzo R, Nicoloso MS, Croce CM and Calin
GA: SnapShot: MicroRNAs in Cancer. Cell. 137:586–586 e581. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhou G, Shi X, Zhang J, Wu S and Zhao J:
MicroRNAs in osteosarcoma: from biological players to clinical
contributors, a review. J Int Med Res. 41:1–12. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li Y, Zhang J, Zhang L, Si M, Yin H and Li
J: Diallyl trisulfide inhibits proliferation, invasion and
angiogenesis of osteosarcoma cells by switching on suppressor
microRNAs and inactivating of Notch-1 signaling. Carcinogenesis.
34:1601–1610. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Asangani IA, Rasheed SA, Nikolova DA, et
al: MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor
suppressor Pdcd4 and stimulates invasion, intravasation and
metastasis in colorectal cancer. Oncogene. 27:2128–2136. 2008.
View Article : Google Scholar
|
|
17
|
Meng F, Henson R, Wehbe-Janek H, Ghoshal
K, Jacob ST and Patel T: MicroRNA-21 regulates expression of the
PTEN tumor suppressor gene in human hepatocellular cancer.
Gastroenterology. 133:647–658. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ziyan W, Shuhua Y, Xiufang W and Xiaoyun
L: MicroRNA-21 is involved in osteosarcoma cell invasion and
migration. Med Oncol. 28:1469–1474. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Montanini L, Lasagna L, Barili V, et al:
MicroRNA cloning and sequencing in osteosarcoma cell lines:
differential role of miR-93. Cell Oncol (Dordr). 35:29–41. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Huang G, Nishimoto K, Zhou Z, Hughes D and
Kleinerman ES: miR-20a encoded by the miR-17-92 cluster increases
the metastatic potential of osteosarcoma cells by regulating Fas
expression. Cancer Res. 72:908–916. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Duan Z, Choy E, Harmon D, et al:
MicroRNA-199a-3p is downregulated in human osteosarcoma and
regulates cell proliferation and migration. Mol Cancer Ther.
10:1337–1345. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Liu LH, Li H, Li JP, et al: miR-125b
suppresses the proliferation and migration of osteosarcoma cells
through down-regulation of STAT3. Biochem Biophys Res Commun.
416:31–38. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhang H, Cai X, Wang Y, Tang H, Tong D and
Ji F: microRNA-143, down-regulated in osteosarcoma, promotes
apoptosis and suppresses tumorigenicity by targeting Bcl-2. Oncol
Rep. 24:1363–1369. 2010.PubMed/NCBI
|
|
24
|
Thayanithy V, Sarver AL, Kartha RV, et al:
Perturbation of 14q32 miRNAs-cMYC gene network in osteosarcoma.
Bone. 50:171–181. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Eis PS, Tam W, Sun L, et al: Accumulation
of miR-155 and BIC RNA in human B cell lymphomas. Proc Natl Acad
Sci USA. 102:3627–3632. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kluiver J, Poppema S, de Jong D, et al:
BIC and miR-155 are highly expressed in Hodgkin, primary
mediastinal and diffuse large B cell lymphomas. J Pathol.
207:243–249. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Provisor AJ, Ettinger LJ, Nachman JB, et
al: Treatment of nonmetastatic osteosarcoma of the extremity with
preoperative and postoperative chemotherapy: a report from the
Children’s Cancer Group. J Clin Oncol. 15:76–84. 1997.
|
|
28
|
Goorin AM, Schwartzentruber DJ, Devidas M,
et al; Pediatric Oncology Group. Presurgical chemotherapy compared
with immediate surgery and adjuvant chemotherapy for nonmetastatic
osteosarcoma: Pediatric Oncology Group Study POG-8651. J Clin
Oncol. 21:1574–1580. 2003. View Article : Google Scholar
|
|
29
|
Lauvrak SU, Munthe E, Kresse SH, et al:
Functional characterisation of osteosarcoma cell lines and
identification of mRNAs and miRNAs associated with aggressive
cancer phenotypes. Br J Cancer. 109:2228–2236. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005.
View Article : Google Scholar
|
|
32
|
Nagarajan R, Weigel BJ, Thompson RC and
Perentesis JP: Osteosarcoma in the first decade of life. Med
Pediatr Oncol. 41:480–483. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Bramwell VH, Burgers M, Sneath R, et al: A
comparison of two short intensive adjuvant chemotherapy regimens in
operable osteosarcoma of limbs in children and young adults: the
first study of the European Osteosarcoma Intergroup. J Clin Oncol.
10:1579–1591. 1992.
|
|
34
|
Bacci G, Picci P, Ferrari S, et al:
Primary chemotherapy and delayed surgery for nonmetastatic
osteosarcoma of the extremities. Results in 164 patients
preoperatively treated with high doses of methotrexate followed by
cisplatin and doxorubicin. Cancer. 72:3227–3238. 1993. View Article : Google Scholar
|
|
35
|
Mora J, Cruz CO, Parareda A and de Torres
C: Treatment of relapsed/refractory pediatric sarcomas with
gemcitabine and docetaxel. J Pediatr Hematol Oncol. 31:723–729.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
McTiernan A and Whelan JS: A Phase II
Study of Docetaxel for the Treatment of Recurrent Osteosarcoma.
Sarcoma. 8:71–76. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Navid F, Willert JR, McCarville MB, et al:
Combination of gemcitabine and docetaxel in the treatment of
children and young adults with refractory bone sarcoma. Cancer.
113:419–425. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
McGary EC, Weber K, Mills L, et al:
Inhibition of platelet-derived growth factor-mediated proliferation
of osteosarcoma cells by the novel tyrosine kinase inhibitor
STI571. Clin Cancer Res. 8:3584–3591. 2002.PubMed/NCBI
|
|
39
|
Sulzbacher I, Birner P, Trieb K, Traxler
M, Lang S and Chott A: Expression of platelet-derived growth
factor-AA is associated with tumor progression in osteosarcoma. Mod
Pathol. 16:66–71. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Kubo T, Piperdi S, Rosenblum J, et al:
Platelet-derived growth factor receptor as a prognostic marker and
a therapeutic target for imatinib mesylate therapy in osteosarcoma.
Cancer. 112:2119–2129. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Kaya M, Wada T, Akatsuka T, et al:
Vascular endothelial growth factor expression in untreated
osteosarcoma is predictive of pulmonary metastasis and poor
prognosis. Clin Cancer Res. 6:572–577. 2000.PubMed/NCBI
|
|
42
|
Kolb EA, Kamara D, Zhang W, et al: R1507,
a fully human monoclonal antibody targeting IGF-1R, is effective
alone and in combination with rapamycin in inhibiting growth of
osteosarcoma xenografts. Pediatr Blood Cancer. 55:67–75.
2010.PubMed/NCBI
|
|
43
|
Manara MC, Nicoletti G, Zambelli D, et al:
NVP-BEZ235 as a new therapeutic option for sarcomas. Clin Cancer
Res. 16:530–540. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Pignochino Y, Grignani G, Cavalloni G, et
al: Sorafenib blocks tumour growth, angiogenesis and metastatic
potential in preclinical models of osteosarcoma through a mechanism
potentially involving the inhibition of ERK1/2, MCL-1 and ezrin
pathways. Mol Cancer. 8:1182009. View Article : Google Scholar
|
|
45
|
Zhang W, Qian JX, Yi HL, et al: The
microRNA-29 plays a central role in osteosarcoma pathogenesis and
progression. Mol Biol (Mosk). 46:622–627. 2012. View Article : Google Scholar : PubMed/NCBI
|
